Baxter: NUMETA G13E Neonatal IV Nutrition Gets UK, Denmark Marketing Approval

(RTTNews) - Baxter International Inc. (BAX) announced Wednesday that it has received Marketing Authorization from the Competent Authorities in the United Kingdom and Denmark for NUMETA G13E 300 mL, a parenteral (intravenous) nutrition or PN product.

The only approved triple-chamber, commercially prepared IV product addresses critical nutritional needs of vulnerable preterm infants (less than 37 weeks gestation age) who are at high risk for malnutrition.

Baxter said these national approvals are the first of 20 European countries where Baxter is seeking authorization for NUMETA G13E in 2016.

NUMETA G13E is indicated for PN administration for neonatal patients when oral or enteral nutrition is impossible, insufficient or contraindicated. NUMETA addresses an important medical need to support neonatal patients who have acute nutritional requirements by providing a balanced formulation of amino acids (protein), glucose (carbohydrates), lipids (fats) and electrolytes in a triple-chamber system that was pioneered by Baxter.